Figure 1.
Recruitment of ATR pathway proteins to sites of DNA damage in uninfected cells.
The ssDNA at sites of damage is coated by Replication protein A (RPA) and recruits ATR through a direct interaction with the ATR interacting protein (ATRIP). This RPA coated ssDNA also promotes the loading of the 9-1-1 (Rad9-Rad1-Hus1) checkpoint clamp by Rad17 onto the junction of the ss/dsDNA. TopBP1 is recruited via an interaction with the phosphorylated C-terminal tail of Rad9. TopBP1 then activates ATR kinase activity resulting in phosphorylation of Chk1, which is promoted by Claspin.
Figure 2.
HSV-1 inhibition of ATR signaling requires ICP8 and UL8.
(A) Vero cells were either mock-infected or infected with HSV-1 at an MOI of 10 PFU/cell. At 5 hours post infection cells were treated with HU for 1 hour or UV and allowed to recover for 1 hour. (B) Vero cells were either mock-infected or infected with HSV-1 at an MOI of 10 PFU/cell. Cells were treated with UV at the indicated time post infection and allowed to recover for 1 hour. (C) Vero cells were either mock-infected or infected with the indicated HSV-1 mutant viruses at an MOI of 10 PFU/cell. At 5 hours post infection cells were treated with UV and allowed to recover for one hour. All cell lysates were analyzed by Western blot with the indicated antibodies. The band marked with an asterisk (*) in the P-RPA-S33 blot corresponds to a non-specific band that does not cross react with antibodies to endogenous RPA and likely represents cross-reactivity with a viral protein.
Table 1.
Summary of HSV-1 mutants ability to disable ATR signaling.
Figure 3.
ICP8 and UL8 are sufficient to inhibit ATR signaling.
(A) U2OS or (B) Vero cells were transfected with ICP8, UL8, UL5, and UL52 (ICP8+H/P) or ICP8 and UL8 alone and then damaged with UV. Cells were fixed at 1 hour post damage and prepared for immunofluorescence as described in the materials and methods. (C) Cells were treated as in A and stained for either P-RPA-S33 or P-RPA-S4/S8. At least 100 cells were counted between two independent experiments.
Figure 4.
UL8 mutants that do not support DNA replication still inhibit ATR signaling.
(A) Schematic of UL8 mutants used in this study. (B) Vero cells were transfected with ICP8, UL5, UL5, and the indicated UL8 mutants and then damaged with UV. Cells were fixed at 1 hour post damage and prepared for immunofluorescence as described in the materials and methods.
Figure 5.
The four-protein complex localizes to sites of DNA damage.
Vero cells were transfected with ICP8, UL8, UL5, and UL52 and BrdU was added at the time of transfection. Cells were treated with UV or HU at 24
Figure 6.
Essential ATR pathway proteins are excluded from the four-protein complex.
Vero cells were transfected with ICP8, UL8, UL5, and UL52 and damaged with UV and allowed to recover for 1-RPA70 or Myc-TopBP1 were cotransfected with the viral proteins. To follow HA-Rad9 Vero cells stably expressing HA-Rad9 were transfected with the viral proteins prior to UV irradiation.
Figure 7.
ATR can be activated in cells expressing the four-protein complex and the ATR Activation Domain of TopBP1.
Vero cells were transfected with GFP-TopBP1-AAD alone or in combination with ICP8, UL8, UL5, and UL52 (ICP8+H/P). Cells were fixed at 18 hours post transfection and prepared for immunofluorescence as described in the materials and methods.
Figure 8.
Model of DNA repair proteins at sites of DNA damage in the presence of the 4-protein complex.
In the presence of ICP8 and helicase/primase, RPA can still coat ssDNA at sites of damage and recruit ATR/ATRIP. However, these four-proteins bind to the ss/dsDNA junction that would normally serve as the loading platform for the 9-1-1 complex and exclude it from binding the DNA. This serves to prevent all of the downstream proteins from being recruited to sites of DNA damage and effectively inhibits ATR signaling.